166 related articles for article (PubMed ID: 21829064)
1. [Treatment strategy for marginally resectable GIST].
Kanda T; Ishikawa T; Ozaki T; Yajima K; Kosugi S; Hatakeyama K
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1266-70. PubMed ID: 21829064
[TBL] [Abstract][Full Text] [Related]
2. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
3. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
4. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Eisenberg BL; Judson I
Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
[TBL] [Abstract][Full Text] [Related]
5. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness.
Kosmadakis N; Visvardis EE; Kartsaklis P; Tsimara M; Chatziantoniou A; Panopoulos I; Erato P; Capsambelis P
Surg Oncol; 2005 Aug; 14(2):75-84. PubMed ID: 15993051
[TBL] [Abstract][Full Text] [Related]
6. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
7. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
8. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Láng I; Hitre E
Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumor: 5 years later.
van der Zwan SM; DeMatteo RP
Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
[TBL] [Abstract][Full Text] [Related]
10. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
11. Gastric GISTs. Personal experience.
Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S
Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
[TBL] [Abstract][Full Text] [Related]
12. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
13. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
[TBL] [Abstract][Full Text] [Related]
14. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
15. [Clinical guidelines for the management of gastrointestinal stromal tumors].
Lopez M; Comandone A; Adamo V; Apice G; Bearzi I; Bracci R; Carlini M; Carpano S; Condorelli S; Covello R; Cucchiara G; Di Filippo F; Doglietto GB; Ficorella C; Garofalo A; Gebbia N; Giuliani F; Massidda B; Messerini L; Palmirotta R; Tonelli F; Vidiri A
Clin Ter; 2006; 157(3):283-99. PubMed ID: 16900856
[TBL] [Abstract][Full Text] [Related]
16. [A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib].
Sakakura C; Miyagawa K; Fukuda K; Kin S; Nakase Y; Kuriu Y; Nakashima S; Yoshikawa T; Yamaoka N; Sagara Y; Hagiwara A; Yamagishi H
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1739-41. PubMed ID: 16315926
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
18. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Hohenberger P; Eisenberg B
Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
[TBL] [Abstract][Full Text] [Related]
19. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
20. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
